A Pyroptosis-Inducing Arsenic(III) Nanomicelle Platform for Synergistic Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Materials Science

Background:

• Immunogenic cell death (ICD) enhances anti-tumor immune responses, offering potential for improved cancer treatments.
• Targeting tumor metabolism and inducing immunogenic cell death are key strategies in cancer therapy.

Purpose of the Study:

• To develop a novel multifunctional agent, Mech02, based on an arsenic(III) pharmacophore for enhanced immunogenic cell death and anti-tumor immunity.
• To investigate the mechanism of Mech02 in inducing pyroptosis, DNA damage, and modulating tumor glycolysis.
• To evaluate the in vivo efficacy of Mech02-loaded nanomicelles (Mech02-HA NPs) in activating anti-tumor immune memory.

Main Methods:

• Synthesis and characterization of the arsenic(III) inhibitor Mech02.
• Investigation of Mech02-induced reactive oxygen species (ROS) generation and pyroptosis.
• Assessment of Mech02's effect on pyruvate kinase M2 (PKM2) binding and glycolysis inhibition.
• Evaluation of DNA damage and cancer stem cell pyroptosis.
• In vivo studies using Mech02-HA NPs to assess immune memory and anti-tumor effects.

Main Results:

• Mech02 induces excessive accumulation of singlet oxygen (¹O₂), leading to pyroptosis and amplified ICD.
• Mech02, converted to Mech03, exhibits enhanced binding to PKM2, disrupting tumor anaerobic glycolysis.
• Mech02 triggers significant DNA damage and pyroptosis in cancer stem cells, promoting tumor clearance.
• In vivo administration of Mech02-HA NPs activates immune memory and sustains anti-tumor immunity.

Conclusions:

• This study introduces arsenic(III) as a novel initiator for enhanced ICD effects within a nitrogen mustard framework.
• Mech02 demonstrates potential as an efficient multimodal therapeutic agent for cancer treatment by combining metabolic disruption and immunogenic cell death.
• The findings provide valuable insights for developing advanced cancer immunotherapies.